

Anti-ERBB3/ HER3 Antibody (Patritumab deruxtecan)

Introduction

Patritumab deruxtecan (HER3-DXd) is an antibody-active molecule conjugate (ADC) composed of the fully human anti-HER3 IgG1 monoclonal antibody patritumab linked to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker [1].

Product parameters

Alternative Names	U3-1402
Target Accession	P21860
Target	ERBB3 / HER3
CAS number	2227102-46-5
Molecular Weight	146.86 kDa
Host	CHO
Reactivity	Human
Conjugation	Dxd
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The drug-to-antibody ratio (DAR) of the Anti-ERBB3/ HER3 Reference Antibody (Patritumab deruxtecan) is 8.0.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

